Nivolumab
欧狄沃(Opdivo)
A PD-1 checkpoint inhibitor immunotherapy (the first approved in China).
At a glance
China price
¥9,260 per (100mg/10mL)
What this meansChecked against a primary or official source.
Source(s)
- https://www.aihope.cn/article/detail/6842
Secondary source (media / community / commercial)
Last checked2026-09-08
NotesNRDL negotiated / (40mg/4mL4591/)
NRDL (national insurance)
Not in NRDL — self-pay.
Regulatory status
NMPA approved; NRDL 202511
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
SourceNo independent source on file.
NotesApproval status from public regulatory reporting.
What it treats
NSCLC, melanoma, gastric and other cancers per Chinese label.
40%-60%33-443-15
Sources & verification
- https://www.aihope.cn/article/detail/6842 — Secondary source (media / community / commercial)
Reader discussion
Public comments about Nivolumab. Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.